A major gift was presented to the lab of Dr. Mel Feany M.D, Ph.D., a professor of Pathology at Harvard Medical School and Brigham and Women's Hospital. Funds from the gift will catalyze efforts to identify new approaches to treating Alexander Disease.

End AxD has also chosen to partner with the UMass Chan Medical School and its Horae Gene Therapy Center to design a gene therapy construct to target AxD. Dr. Guangping Gao, Director of the center, is one of the world's leading experts in the field of AAV gene therapy. Thanks to Yukari Blumenthal for bringing this opportunity to our attention.

We are grateful for the physicians, researchers, and to our donors who help make these investments possible!